Table 1 Characteristics of patients with rheumatoid arthritis ( n = 192)
Age (years) | 55 (45.3 to 62) |
Women | 176 (91.7) |
Disease duration (years) | 9 (4 to 15) |
ESR (mm/hour) | 35 (20 to 50) |
CRP (mg/l) | 1.7 (0.5 to 5.5) |
DAS28 | 3.1 (2.5 to 4.1) |
TNFα (pg/ml) | 3.8 (2.7 to 5.3) |
IL-6 (pg/ml) | 2.3 (1.7 to 5.5) |
Adiponectin (μg/ml) | 192 (136.1 to 293.7) |
Leptin (ng/ml) | 7.7 (3.7 to 13.5) |
L:A ratio × 105 | 3.64 (1.55 to 8.65) |
Resistin (ng/ml) | 4.7 (2.4 to 8.3) |
Metabolic syndrome features | Â |
 Metabolic syndrome | 27 (14.1) |
 Waist circumference (cm) | 77 (72 to 82.4) |
 Glucose (mg/dl) | 86 (81 to 91) |
 Triglycerides (mg/dl) | 94 (70 to 122) |
 HDL cholesterol (mg/l) | 56 (47 to 65.8) |
 SBP (mmHg) | 124 (114 to 134) |
 Hypertension | 70 (36.5) |
 HOMA-IR | 1.46 (0.96 to 2.27) |
Nonmetabolic cardiovascular risk factors | Â |
 BMI (kg/m2) | 22.3 (20.2 to 24.6) |
 Total cholesterol (mg/dl) | 184 (163 to 209.8) |
 LDL cholesterol (mg/dl) | 107.2 (91.2 to 129.4) |
 Smoking history | 19 (9.9) |
 Mean CCA RI | 0.63 (0.60 to 0.66) |
 Mean CCA IMT (mm) | 0.59 (0.51 to 0.68) |
 Total plaque number | 2 (1 to 3) |
 Total plaque volume (cm3) | 0.02 (0 to 0.09) |
Medications | Â |
 Methotrexate | 189 (98.4) |
 Leflunomide | 125 (65.1) |
 Sulfasalazine | 135 (70.3) |
 Hydroxychloroquine | 92 (47.9) |
 Biologicsa | 43 (22.3) |